

# Yukon Immunization Program Manual

## Section 8 — Biological Products

### Hib Vaccine

## Table of Contents

---

Haemophilus b Conjugate Vaccine Act-HIB® .....	1
Table 1. Conditions associated with increased risk of invasive Hib disease.....	1

<b>Haemophilus b Conjugate Vaccine</b>		<b>Act-HIB®</b>	
<b>Manufacturer</b>	Sanofi Pasteur Limited	<b>Biological Classification</b>	Reconstituted non-live conjugate subunit vaccine
<b>Current Formulation</b>	Protection against Haemophilus influenzae type b (Hib)		
<b>INDICATIONS</b>	<b>Routine Pediatric Schedule</b>		
	Act-HIB® is not routinely used for healthy children 2 to 59 months of age in the Yukon, as Hib protection is normally provided through combination vaccines (DTaP-IPV-HB-Hib or DTaP-IPV-Hib).		
	If Hib vaccine is required for a child in this age group outside the routine schedule, consult the Yukon Immunization Program for direction prior to administration.		
	<b>Individuals at Increased Risk of Invasive Hib Disease</b>		
	Act-HIB® may be used for individuals ≥5 years of age with conditions associated with increased risk of invasive Hib disease. See Table 1 for eligible conditions and schedule.		
	<b>Case Management, Contact Follow-Up, and Outbreak Management</b>		
Act-HIB® may be recommended under the direction of Yukon Communicable Disease Control (YCDC) for case management, contact follow-up, or outbreak management, including when chemoprophylaxis is indicated. Consult YCDC for more information.			
<b>Table 1. Conditions associated with increased risk of invasive Hib disease</b>			
<b>Condition</b>		<b>Schedule</b>	
Asplenia or hyposplenism (including sickle cell disease)		1 dose of 0.5 mL IM ≥1 year after any previous Hib dose	
Cochlear implant			
Congenital (primary) immunodeficiency			
HIV infection			
Malignant hematologic disorders		1 dose of 0.5 mL IM ≥1 year regardless of immunization history	
Solid organ transplant			
Hematopoietic stem cell transplant (HSCT)			
<b>AVAILABLE FORMAT</b>	<ul style="list-style-type: none"> <li>Supplied as cartons containing 5 single-dose vials with 5 single-dose diluent vials for reconstitution (0.5 mL per dose).</li> </ul>		

<b>Haemophilus b Conjugate Vaccine</b>		<b>Act-HIB®</b>
<b>CONTRAINDICATIONS</b>	<ul style="list-style-type: none"> <li>• History of anaphylactic reaction to a previous dose or to any component of a Hib-containing vaccine</li> <li>• History of anaphylactic reaction to tetanus protein-containing vaccines</li> </ul>	
<b>PRECAUTIONS &amp; SPECIAL CONSIDERATIONS</b>	<ul style="list-style-type: none"> <li>• <b>Splenectomy:</b> Give vaccine <math>\geq 14</math> days before surgery. If this is not possible, give <math>\geq 14</math> days after splenectomy</li> <li>• <b>Acute illness:</b> Defer immunization in moderate or severe acute illness. Minor illness, with or without fever, is not usually a reason to delay immunization.</li> <li>• <b>Additional Hib doses:</b> Extra doses of Hib-containing vaccine are not harmful and may be given when required to complete a combination vaccine schedule or when prior immunization history is uncertain.</li> <li>• <b>Premature infants:</b> immunize according to chronological age</li> </ul>	
<b>PREGNANCY AND LACTATION</b>	<ul style="list-style-type: none"> <li>• <b>Pregnancy:</b> not routinely indicated but may be given if clinically indicated</li> <li>• <b>Lactation:</b> safe</li> </ul>	
<b>INTERCHANGEABILITY</b>	Use the same Hib product when possible. If unavailable, another Hib vaccine may be used to complete the series.	
<b>RECONSTITUTION AND DILUTION</b>	Reconstitute with supplied diluent and administer immediately after mixing	
<b>ADMINISTRATION</b>	<ul style="list-style-type: none"> <li>• <b>Dose:</b> 0.5 mL</li> <li>• <b>Route:</b> Intramuscular (IM)</li> <li>• <b>Preferred site:</b> <ul style="list-style-type: none"> <li>○ Infants: anterolateral thigh</li> <li>○ Children <math>&gt;1</math> year and adults: deltoid preferred</li> </ul> </li> <li>• <b>After reconstitution:</b> administer the entire contents of the vial</li> </ul>	
<b>CONCURRENT ADMINISTRATION WITH OTHER VACCINES</b>	May be given with other vaccines using separate injection sites	

<b>Haemophilus b Conjugate Vaccine</b>		<b>Act-HIB®</b>
<b>SEROLOGICAL TESTING</b>	Not recommended before or after immunization	
<b>VACCINE COMPONENTS</b>	<ul style="list-style-type: none"> <li>• Hib polysaccharide (PRP) conjugated to tetanus protein</li> <li>• Contains sucrose, Tris, and sodium chloride (diluent)</li> </ul>	
<b>APPEARANCE</b>	<ul style="list-style-type: none"> <li>• <b>Before reconstitution:</b> white lyophilized powder</li> <li>• <b>After reconstitution:</b> clear, colourless solution</li> </ul>	
<b>BLOOD/ BLOOD PRODUCTS</b>	None	
<b>BOVINE/ PORCINE PRODUCTS</b>	None	
<b>LATEX</b>	None	
<b>EXPECTED REACTIONS</b>	<ul style="list-style-type: none"> <li>• <b>Local reactions:</b> pain, redness, swelling at the injection site</li> <li>• <b>Systemic reactions:</b> fever</li> </ul>	
<b>STORAGE AND HANDLING</b>	<b>Storage:</b>	
	<ul style="list-style-type: none"> <li>• Store at +2°C to +8°C</li> <li>• Do not freeze</li> </ul>	
	<b>Handling</b>	
	<ul style="list-style-type: none"> <li>• Reconstitute using the supplied diluent</li> <li>• Administer the full contents of the reconstituted vaccine</li> <li>• Use immediately after reconstitution</li> </ul>	
<b>REFERENCES AND RESOURCES</b>		
<a href="#">National Advisory Committee on Immunization Statements</a> <a href="#">Canadian Immunization Guide</a> <a href="#">Product Monograph</a>		